aducanumab-avwa injection

Aducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer’s disease (AD). It is an amyloid beta-directed monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer’s disease to reduce its buildup. It was developed by Biogen and Eisai.

Are you looking for or in search of FDA approved “aducanumab-avwa injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Alzheimer. Need Access of aducanumab-avwa injection, get in touch with our healthcare professional.

aducanumab-avwa injection price in Latin America, Russia, UK and USA.
aducanumab-avwa injection

Aducanumab is indicated for the treatment of Alzheimer’s disease. In July 2021, the U.S. Food and Drug Administration (FDA) limited the indication to people with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Aducanumab is a monoclonal IG1 antibody that binds to the amyloid beta protein at amino acids 3–7, which is posited to result in slowing the progression of Alzheimer’s disease.

Aducanumab was approved for medical use in the United States by the Food and Drug Administration (FDA) in June 2021,[8] in a controversial decision that led to the resignation of three advisers to the FDA in the absence of evidence that the drug is effective. The FDA stated that it represents a first-of-its-kind treatment approved for Alzheimer’s disease and that it is the first new treatment approved for Alzheimer’s since 2003. Aducanumab’s approval is controversial due to ambiguous clinical trial results surrounding its efficacy.

    aducanumab-avwa injection

    Contact No.

    Call us
    +91 11 4350 7259

    Emergency Contact
    +91 93139 48015


    Visit us anytime
    F-90/1 , Okhla Industrial Area,
    Phase -1 , New Delhi. India

    Send us an email